Del Mar Pharmaceuticals has filed an investigational new drug (IND) application with the United States FDA to conduct clinical trials with VAL-083 in patients diagnosed with glioblastoma multiforme. We are in the process of responding to the FDA’s questions on our application and anticipate initiating the clinical trial during the coming months.
Please check back to this page for updates. Study site and enrollment information will be provided here upon approval of our trial by the FDA.